Trials / Completed
CompletedNCT01173770
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ADC3680B in Healthy Volunteers
A Double-Blind Randomized, Placebo-Controlled, Dose Escalating Study to Assess The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ADC3680B Administered Orally to Healthy Volunteers and to Investigate Food Effects on Pharmacokinetics After Single Oral Doses of ADC3680B
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Pulmagen Therapeutics · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a First-In-Man study designed to examine the safety, tolerability, pharmacokinetics and functional activity of ADC3680B after single and multiple doses in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADC3680B | Escalating single doses ADC3680B or Placebo over 5 study periods |
| DRUG | ADC3680B | ADC3680B or Placebo for 7 days |
| DRUG | ADC3680B | Single doses ADC3680B over 2 study periods under fasted and fed conditions |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2010-08-02
- Last updated
- 2011-02-02
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01173770. Inclusion in this directory is not an endorsement.